Neurodegeneration after traumatic brain injury is facilitated by innate and adaptive immunity and can be harnessed to affect brain repair. In mice subjected to controlled cortical impact (CCI), we show that treatment with granulocyte macrophage colony stimulating factor (GM-CSF) affects regulatory T cell numbers in the cervical lymph nodes coincident with decreased lesion volumes and increased cortical tissue sparing. This paralleled increases in neurofilament and diminished reactive microglial staining. Transcriptomic analysis showed that GM-CSF induces robust immune neuroprotective responses seven days following CCI. Together, these results support the therapeutic potential of GM-CSF for TBI.
Introduction
Traumatic brain injury (TBI) leads to chronic neurodegeneration driven, in part, by innate and adaptive immune responses. Both influence neuronal injury (Jin et al., 2012) . Brain shearing forces affect mechanical trauma causing release of purinergic signaling molecules (Davalos et al., 2005) , excitatory neurotransmitters (Faden et al., 1989; Palmer et al., 1993) , and other damage-associated factors (Laird et al., 2014) . These affect resident glial (astrocytes and microglia) function leading to the production of pro-inflammatory mediators. These include reactive oxygen species, cytokines and pro-apoptotic proteins; all known to perpetuate neural injury (Burda and Sofroniew, 2014) . Notably, the traumatic event can damage the neurovasculature and attract immunocytes, such as neutrophils, lymphocytes and blood-borne macrophages, to sites of brain injury (Soares et al., 1995; Carlos et al., 1997; Schwarzmaier et al., 2010) . Once in the parenchyma, the cells can become immune competent, affecting glial responses and accelerating ongoing neural damage. Such changes can affect microglial responses, where a pro-inflammatory, classically activated state (M1) and an anti-inflammatory, alternatively activated state (M2) evolve in a temporally ordered fashion over prolonged time periods (Loane et al., 2014) . Indeed, long-term immune response changes were observed in human brains up to 17 years after brain injury (Ramlackhansingh et al., 2011) .
The role of the adaptive immunity in the pathobiology of TBI is heralded by a steady increase in the number of lymphocytes that enter the brain, but not in draining lymph nodes or spleen (Clausen et al., 2009; Jin et al., 2012) . Such cellular shifts occur as early as one day following injury and can continue for up to 28 days after the traumatic event. Whether the cells serve to accelerate damage or perform homeostatic functions is not understood. Previous work by our group and others demonstrated that regulatory T cells (Tregs) can attenuate microglial pro-inflammatory activities leading to robust neuroprotective responses in models of stroke, HIV-1 encephalitis, amyotrophic lateral sclerosis, myasthenia gravis and Parkinson's disease (PD) (Reynolds et al., 2007; Sheng et al., 2008; Liesz et al., 2009; Reynolds et al., 2009; Reynolds et al., 2010; Gendelman and Appel, 2011; Kosloski et al., 2013; Li et al., 2013) .
As neurodegenerative and neuroinflammatory disorders, immune activity changes with time following TBI (Kox et al., 2008; Jin et al., 2012; Loane et al., 2014) . The dynamics of immune mediated injuries versus neuroprotection are also controlled by environmental events and immune regulatory activities (Burda and Sofroniew, 2014) . The transformation of innate microglial and astrocyte activities together with the emergence of an altered adaptive immune response can certainly aggravate neural damage (Jin et al., 2012) . Such events are operative immediately following injuries but, interestingly, evolve over time leading to compensatory neuroprotective outcomes (Ziebell et al., 2014) . On the cellular level, astrocytes contribute to these complex immunoregulatory events by affecting blood-brain barrier integrity and microglial secretory responses that include the production of neuroregulatory and neuroprotective factors to speed neuronal repair (Segev-Amzaleg et al., 2013) . The degree and timing of cell-based cross-talk are nonetheless limited for TBI, leaving open the notion that Journal of Neuroimmunology 278 (2015) [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] 
